Oura Expands Its Menopause Impact Scale Into Clinical Care Through New Partner Network

Oura has announced an expansion of its proprietary Menopause Impact Scale (MIS) through a new network of ten partners spanning specialty menopause care, primary care, telehealth, and hormone tracking, according to the Oura Blog. The move is designed to move the MIS beyond the Oura app and ring ecosystem and into the hands of clinicians and care platforms that many perimenopausal and menopausal patients already use.

The partners named in the announcement are Alloy Health, Oova, Xella, Pomelo, Wisp, Maven, Mira, Hertility, Gennev, and Tia, as Oura reported. That list covers a broad slice of the women's health tech landscape — from telehealth prescribers and fertility/hormone testing companies to dedicated menopause care platforms — suggesting Oura is positioning the MIS as a shared data layer rather than a feature locked inside its own app.

What the Menopause Impact Scale Is Trying to Solve

Oura describes the MIS as proprietary, built to quantify how menopause-related symptoms and physiological shifts show up in a person's day-to-day data. For readers of this site, that's notable: menopause and perimenopause are transition periods where the same biometric signals wearables already track for cycle-syncing purposes — sleep quality, resting heart rate patterns, and heart rate variability — can shift in ways that aren't captured by standard cycle-phase tracking once ovulation becomes irregular or stops altogether.

Traditional cycle-based training and recovery frameworks lean on a fairly predictable follicular/luteal structure. Menopause breaks that structure. Hot flashes, disrupted sleep, and changes in autonomic balance can all affect recovery metrics without a clean hormonal cycle to explain them. A standardized scale like the MIS is, at least in principle, an attempt to give both users and clinicians a consistent way to describe that impact rather than relying on symptom checklists alone — though Oura's announcement does not detail the specific inputs, scoring methodology, or validation data behind the scale, and readers should treat those mechanics as still largely proprietary and undisclosed.

Why Clinical Integration Matters

The significance of this announcement isn't the scale itself — Oura has offered menopause-related tracking within its own app before — but the decision to route it through outside clinical and telehealth partners, according to the Oura Blog. Menopause care has historically been fragmented: a patient might see a primary care provider, a telehealth prescriber for hormone therapy, and a separate hormone-testing service, often without any of those parties sharing a common dataset. By pushing the MIS into platforms like Maven, Tia, Gennev, and Alloy Health, Oura is betting that a wearable-derived symptom score can act as a common reference point across that fragmented care journey.

For hormone-tracking-specific partners such as Oova and Mira, which focus on testing reproductive hormones, the integration could theoretically pair lab or at-home hormone data with the continuous, passive signal a ring provides overnight and throughout the day. Oura's announcement frames this as extending the MIS's reach rather than announcing a specific new clinical outcome, so it's worth being precise about what has and hasn't been claimed here: this is a distribution and integration announcement, not a study release, and no accuracy figures, validation results, or clinical outcome data are included in the source material.

What This Means for Cycle-Syncing Wearable Users

For the growing number of people using wearables to sync training, recovery, and even nutrition to their menstrual cycle, this expansion is a reminder that cycle-based frameworks eventually need a menopause-specific counterpart. Perimenopause in particular can produce irregular cycles that make phase-based training guidance less reliable, and a menopause-specific scale — if it proves useful — could give athletes and everyday users a different lens once classic cycle tracking stops being applicable.

That said, the practical value of the MIS for an individual user will likely depend on execution details Oura hasn't published in this announcement: how symptoms are weighted, how the scale interacts with existing Oura Readiness and Sleep scores, and whether any of the ten new partners will surface MIS data back to users in a format that's actionable for training or recovery decisions. Until Oura or its partners publish more granular information, the MIS should be understood as a symptom-tracking and care-coordination tool rather than a validated clinical diagnostic — and nothing here should be read as medical advice or used to self-diagnose menopausal status.

The Bigger Picture

Wearable companies have increasingly treated women's health as a distinct product category rather than an afterthought, and Oura has been one of the more visible players in that shift with cycle tracking and now menopause-specific tooling. Partnering with ten healthcare and hormone-tracking companies at once, according to Oura's own announcement, signals an attempt to become infrastructure for menopause care broadly — not just a feature inside one ring's app. Whether that ecosystem play translates into meaningfully better symptom management or clinical decision-making for menopausal users remains to be seen, since the current announcement is about network expansion, not published outcomes.

For now, the practical takeaway for wearable users tracking their cycle or transitioning into perimenopause is straightforward: keep an eye on whether your existing hormone-tracking or telehealth provider is on Oura's new partner list, since that may be the first place expanded MIS data shows up outside the Oura app itself.